Efficacy of Halofantrine Hydrochloride in vivax malaria

Journal of Postgraduate Medical Institute

Volumn 19, Issue 3, 2005, Pages 276-280

  Khan, Shiraz Jamal ^a   Munib, Syed ^a  

^a Gomal Medical College   (Pakistan)

Author keywords

Halofantrine Hydrochloride; Malaria; Malaria resistance; Plasmodium vivax

Indexed keywords

HALOFANTRINE;

ADULT; ARTICLE; BLOOD ANALYSIS; BODY TEMPERATURE MONITORING; CLINICAL FEATURE; CONTROLLED STUDY; CULTURE TECHNIQUE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; ECG ABNORMALITY; FEMALE; FEVER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; PAKISTAN; PLASMA CLEARANCE; PLASMODIUM VIVAX; RELAPSE; TABLET FORMULATION;

EID: 33646170681     PISSN: 10135472     EISSN: 18119387     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Garcia, LS. Malaria and Babesiosis. In: Garcia LS. Editor. Diagnostic Medical Parasitology. Washington, DC: American Society for Microbiology; 2001; 159204.
2. White, NJ. Malaria. In: Cook GC, Zumla AI, Weir 3. Editor. Manson's Tropical Diseases. Philadelphia, PA: WB Saunders; 2003; 12051295.
3. White NJ: The assessment of antimalarial drug efficacy. Trends Parasitol 2002;18: 865.
4. Hayton K, Su XZ. Genetic and biochemical aspects of drug resistance in malaria parasites.Curr Drug Targets Infect Disord. 2004; 4(1):1-10.
5. Kasper DL, Braunwald E, Fauci AS et al. Harrison's Principles of Internal Medicine, Mc Graw-Hill 16th edition; 2005; 1220.
6. Khan M A, Smego RA, Razi S T, Beg M A. Emerging drug-resistance and guidelines for treatment of malaria. J Coll Physicians Surg Pak 2004;14 (50):319-24.
7. Nicolas X, Granier H, Laborde ]P, Talarmin F, Klotz F. Plasmodium Vivax: therapy update. Presse Med 2001; 30(15):767-71.
8. Tracy JW, Webster LT: Drugs used in the chemotherapy of protozoal infections: Malaria. In: Hardman JC, Limbird LE (Eds). Goodman and Gliman's The Pharmacological Basis of Therapeutics, 10th ed, New York Mc Graw- hill, 2002; 1069-1140.
9. Halfan (Halofantrine Hydrochloride): prescribing information Leaflet, Glaxo Smith Kline.
10. Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop. 2004;89(3):351-6
11. Taylor WR, Doan HN, Nguyen DT, Tran TU, Fryauff DJ, Gomez-Saladin E, et al. Assessing drug sensitivity of plasmodium vivax to halofantrine or choroquine in southern, central Vietnam using an extended 28-day in vivo test and polymerase chain reaction genotyping. Am J Trop Med Hyg. 2000;62(6):693-7.
12. Kain KC. Chemotherapy and prevention of drug-resistant malaria. Wilderness Environ Med 1995;6(3):307-24.
13. Le Bras J, Longuet C, Charmot G. Human transmission and plasmodium resistance. Rev Prat 1998;48(3):258-63.
14. Kager PA, Wetsteyn X. Malaria and drug resistance. Ned Tijdschr Geneeskd 1996;140(3):151-5.
15. Nosten F, Price RN. New antimalarials. A risk- benefit analysis. Drug Saf 1995;12(4):264-73.
16. Khan Z, Shoalb S, Ahmed T M, Maqbool S, Isani Z, Mehmood K, et al. Efficacy and safety of Halofantrine hydrochloride in malaria treatment. J Pakistan Inst Med Sci 2004;15(1):853-6